Novo Nordisk is committed to meeting its responsibility to respect human rights as defined by the UN Guiding Principles on Business and Human Rights. As such we will:
The responsibility to respect human rights refers to all internationally recognised human rights, including but not limited to prohibition of forced, bonded or debt labour, slavery, servitude and human trafficking.
In implementing the UN Guiding Principles, we will pay particular attention to the rights of, as well as the challenges faced by, vulnerable groups whom we have impacts, such as children and patients, by referring to relevant United Nations instruments (e.g. Convention on the Rights of the Child).
We expect every employee to understand this responsibility and thereby treat everyone with respect. We are accountable and we never compromise on business ethics, according to the company values expressed in Novo Nordisk Way.
The responsibility of Human Rights is anchored under the Business Ethics Compliance Office (BECO) in Novo Nordisk. The human rights commitment is an integral part of the Business Ethics Code of Conduct and is overseen by the Business Ethics Committee.
This commitment is approved by Lars Fruergaard Jørgensen, President & CEO of Novo Nordisk. (6 December 2018)
We conduct regular assessment of our risks and impacts on all human rights across our global processes and corporate functions. The assessment consists of desk research, expert and peer inputs, engagement with stakeholders including patient representatives and cross-organisational review.
Among the human rights impacts we have identified, the following were determined as our salient human rights issues and important human rights impacts for 2018-2019. These have been prioritised for due diligence and reporting. Find out below how we manage each of these human rights issues and impacts: